Literature DB >> 9044834

Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion.

J Gray-Bablin1, S Rao, K Keyomarsi.   

Abstract

Cyclin-dependent kinase inhibitors (CKIs) p21, p27, p16, and p15 are an essential and integral part of cell cycle regulation. Studies on the expression of these inhibitors in normal versus tumor human breast cancer cells revealed that although p27 and p16 are expressed at higher levels in tumor cells, p21 and p15 expression were higher in normal cells. Analysis on the expression pattern of these proteins throughout the cell cycle in synchronized cells demonstrated a substantial increase in p21 during the S-phase in normal cells and barely detectable expression of p21 in any phase of the tumor cell cycle. Levels of p15, p16, and p27 remained relatively constant throughout the cell cycle of normal and tumor cells. Synchronization of tumor cells by lovastatin, which arrests cells in G1, resulted in increased levels of p21 and p27 with a concomitant decrease in cyclin-dependent kinase 2-associated kinase activity. Synchronization of cells by double-thymidine block did not result in the induction of p21 or p27. These observations suggest that lovastatin causes a profound cell cycle-independent alteration of CKI expression which is distinct from growth factor deprivation or thymidine block.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9044834

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  NoBP, a nuclear fibroblast growth factor 3 binding protein, is cell cycle regulated and promotes cell growth.

Authors:  K Reimers; M Antoine; M Zapatka; V Blecken; C Dickson; P Kiefer
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

2.  Alcoholic liver disease - Hepatocellular carcinoma transformation.

Authors:  Samuel W French; James Lee; Jim Zhong; Timothy R Morgan; Virgil Buslon; William Lungo; Barbara A French
Journal:  J Gastrointest Oncol       Date:  2012-09

3.  Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.

Authors:  S Rao; D C Porter; X Chen; T Herliczek; M Lowe; K Keyomarsi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

4.  Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a).

Authors:  J Mitra; C Y Dai; K Somasundaram; W S El-Deiry; K Satyamoorthy; M Herlyn; G H Enders
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

5.  Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.

Authors:  Jean-Pierre H Perchellet; Elisabeth M Perchellet; Kyle R Crow; Keith R Buszek; Neil Brown; Sampathkumar Ellappan; Ge Gao; Diheng Luo; Machiko Minatoya; Gerald H Lushington
Journal:  Int J Mol Med       Date:  2009-11       Impact factor: 4.101

Review 6.  Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases.

Authors:  Paolo Calabro; Edward T H Yeh
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

7.  Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.

Authors:  Adam R Wolfe; Bisrat G Debeb; Lara Lacerda; Richard Larson; Arvind Bambhroliya; Xuelin Huang; Francois Bertucci; Pascal Finetti; Daniel Birnbaum; Steven Van Laere; Parmeswaran Diagaradjan; Brian Ruffell; Nicholaus J Trenton; Khoi Chu; Walter Hittelman; Michael Diehl; Ilya Levental; Naoto T Ueno; Wendy A Woodward
Journal:  Breast Cancer Res Treat       Date:  2015-11-21       Impact factor: 4.872

8.  In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent.

Authors:  Elena Maksimova; Ting-An Yie; William N Rom
Journal:  Lung       Date:  2007-11-22       Impact factor: 2.584

9.  The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis.

Authors:  J Follet; L Corcos; G Baffet; F Ezan; F Morel; B Simon; C Le Jossic-Corcos
Journal:  Br J Cancer       Date:  2012-01-31       Impact factor: 7.640

Review 10.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.